bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
06 Mai 2024 - 1:05PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it
will host a conference call to discuss first quarter 2024 results
and business updates on May 9, at 8:00 a.m. ET.
To participate in the conference call, please dial +1 (800)
715-9871 (U.S. and Canada) and ask to be joined into the bluebird
call or provide the Conference ID 9768329.
In addition, members of the management team will participate in
the following upcoming investor conferences:
- BofA Securities 2024 Health Care Conference, Thursday, May 16,
at 10:00 a.m. PT (1:00 p.m. ET) in Las Vegas, NV
- Goldman Sachs 45th Annual Global Healthcare Conference,
Wednesday, June 12, at 11:20 a.m. ET in Miami Beach, FL
To access the live webcasts of bluebird bio’s first quarter
results conference call and fireside chats, please visit the
“Events & Presentations” page within the Investors & Media
section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcasts will be
available on the bluebird bio website for 90 days following the
events.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506060424/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024